OpenArc Corporate Advisory’s Vertex Pharmaceuticals VRTX Stock Holding History

OpenArc Corporate Advisory’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.07M	Buy	2,395 +550	+30%	+$256K	0.02%	315
2025 Q4	$836K	Buy	+1,845	New	+$795K	0.01%	318

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

OpenArc Corporate Advisory's VRTX Position: Q1 2026 in Review

OpenArc Corporate Advisory increased its Vertex Pharmaceuticals (VRTX) stake by 30% in Q1 2026, buying an estimated $256K and bringing the position to 2,395 shares worth $1.07M. The position accounts for 0.02% of the portfolio, ranked #315.

OpenArc Corporate Advisory first reported a position in VRTX in Q4 2025 and has held it in 2 quarters since. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.

OpenArc Corporate Advisory held 2,395 shares of Vertex Pharmaceuticals worth $1.07M as of Q1 2026.
OpenArc Corporate Advisory bought 550 Vertex Pharmaceuticals shares in Q1 2026, an estimated $256K.
Vertex Pharmaceuticals made up 0.02% of OpenArc Corporate Advisory's portfolio in Q1 2026, its #315 holding.
OpenArc Corporate Advisory first reported a position in Vertex Pharmaceuticals in Q4 2025 and has held it in 2 quarters since.
1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.

Based on OpenArc Corporate Advisory's 13F filing for Q1 2026, filed 11 May 2026.